{"id":49798,"date":"2025-12-02T22:48:48","date_gmt":"2025-12-02T14:48:48","guid":{"rendered":"https:\/\/flcube.com\/?p=49798"},"modified":"2025-12-02T22:48:49","modified_gmt":"2025-12-02T14:48:49","slug":"henlius-hlx37-bispecific-nmpa-approval-targets-advanced-solid-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=49798","title":{"rendered":"Henlius HLX37 Bispecific NMPA Approval Targets Advanced Solid Tumors"},"content":{"rendered":"\n<p><strong>Shanghai Henlius Biotech, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2696:HKG\">HKG: 2696<\/a>) announced that its self-developed investigational new drug, <strong>HLX37<\/strong> (Recombinant Humanized Anti-PD-L1 and Anti-VEGF Bispecific Antibody), has received approval from the <strong>China National Medical Products Administration (NMPA)<\/strong> to conduct a <strong>Phase I clinical study<\/strong> for the treatment of advanced\/metastatic solid tumors.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone-amp-drug-profile\">Regulatory Milestone &amp; Drug Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Shanghai Henlius Biotech, Inc. (2696.HK)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>HLX37<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Recombinant humanized anti-PD-L1 and anti-VEGF bispecific antibody<\/td><\/tr><tr><td><strong>Approval<\/strong><\/td><td>NMPA Phase I clinical study IND approval<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Advanced\/metastatic solid tumors<\/td><\/tr><tr><td><strong>Innovation<\/strong><\/td><td>Dual-target design targeting both immunosuppression and angiogenesis<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mechanism-of-action-amp-differentiation\">Mechanism of Action &amp; Differentiation<\/h2>\n\n\n\n<p>HLX37 combines two therapeutic pathways in a single bispecific antibody:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>PD-L1 Blockade<\/strong>: Blocks binding of PD-L1 on tumor cells to PD-1 on immune cells (e.g., T-cells), releasing tumor immunosuppression and restoring T-cell cytotoxicity<\/li>\n\n\n\n<li><strong>VEGF Inhibition<\/strong>: Targets VEGF to reduce tumor angiogenesis, limiting blood supply for tumor growth and metastasis<\/li>\n\n\n\n<li><strong>Synergistic Design<\/strong>: Dual-target approach expected to generate synergistic anti-tumor effects and potentially reduce drug resistance<\/li>\n\n\n\n<li><strong>Tumor Microenvironment Enrichment<\/strong>: Specific binding to PD-L1 on tumor cells facilitates enrichment of the anti-VEGF functional domain within the tumor microenvironment<\/li>\n\n\n\n<li><strong>Competitive Advantage<\/strong>: Aims to achieve greater therapeutic effect than the combination of separate anti-PD-L1 and anti-VEGF monoclonal antibodies<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-path\">Clinical Development Path<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Study Design<\/th><th>Timeline<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase I<\/strong><\/td><td>Safety, tolerability, and preliminary efficacy in advanced\/metastatic solid tumors<\/td><td>Initiation Q1\u202f2026<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>Dose escalation and expansion cohorts; potential combination studies<\/td><td>2026-2027<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-strategic-outlook\">Market Context &amp; Strategic Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Solid Tumor Market<\/strong>: China has >4 million new solid tumor cases annually; targeted therapy market exceeds $15 billion<\/li>\n\n\n\n<li><strong>Bispecific Antibody Trend<\/strong>: Dual-target biologics gaining traction as next-generation cancer immunotherapies<\/li>\n\n\n\n<li><strong>Competitive Landscape<\/strong>: HLX37 enters a crowded but growing market; differentiation through co-localization mechanism<\/li>\n\n\n\n<li><strong>Pipeline Synergy<\/strong>: Strengthens Henlius&#8217; oncology portfolio alongside its established PD-1 inhibitor portfolio<\/li>\n\n\n\n<li><strong>Global Potential<\/strong>: China approval pathway may support future US\/EU development strategies<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding HLX37 development timelines, clinical outcomes, and market potential. Actual results may differ due to clinical, regulatory, and competitive uncertainties.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that its self-developed investigational new drug, HLX37 (Recombinant&#8230;<\/p>\n","protected":false},"author":1,"featured_media":49799,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,62,270,862,28,18],"class_list":["post-49798","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-henlius-biotech","tag-hkg-2696","tag-multi-specific-antibodies","tag-pd-1-l1"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Henlius HLX37 Bispecific NMPA Approval Targets Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that its self-developed investigational new drug, HLX37 (Recombinant Humanized Anti-PD-L1 and Anti-VEGF Bispecific Antibody), has received approval from the China National Medical Products Administration (NMPA) to conduct a Phase I clinical study for the treatment of advanced\/metastatic solid tumors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=49798\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Henlius HLX37 Bispecific NMPA Approval Targets Advanced Solid Tumors\" \/>\n<meta property=\"og:description\" content=\"Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that its self-developed investigational new drug, HLX37 (Recombinant Humanized Anti-PD-L1 and Anti-VEGF Bispecific Antibody), has received approval from the China National Medical Products Administration (NMPA) to conduct a Phase I clinical study for the treatment of advanced\/metastatic solid tumors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=49798\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-02T14:48:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-02T14:48:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0210.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49798#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49798\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Henlius HLX37 Bispecific NMPA Approval Targets Advanced Solid Tumors\",\"datePublished\":\"2025-12-02T14:48:48+00:00\",\"dateModified\":\"2025-12-02T14:48:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49798\"},\"wordCount\":343,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49798#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0210.webp\",\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"Henlius Biotech\",\"HKG: 2696\",\"Multi-specific antibodies\",\"PD-1\\\/L1\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49798#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49798\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=49798\",\"name\":\"Henlius HLX37 Bispecific NMPA Approval Targets Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49798#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49798#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0210.webp\",\"datePublished\":\"2025-12-02T14:48:48+00:00\",\"dateModified\":\"2025-12-02T14:48:49+00:00\",\"description\":\"Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that its self-developed investigational new drug, HLX37 (Recombinant Humanized Anti-PD-L1 and Anti-VEGF Bispecific Antibody), has received approval from the China National Medical Products Administration (NMPA) to conduct a Phase I clinical study for the treatment of advanced\\\/metastatic solid tumors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49798#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49798\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49798#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0210.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0210.webp\",\"width\":1080,\"height\":608,\"caption\":\"Henlius HLX37 Bispecific NMPA Approval Targets Advanced Solid Tumors\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49798#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Henlius HLX37 Bispecific NMPA Approval Targets Advanced Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Henlius HLX37 Bispecific NMPA Approval Targets Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that its self-developed investigational new drug, HLX37 (Recombinant Humanized Anti-PD-L1 and Anti-VEGF Bispecific Antibody), has received approval from the China National Medical Products Administration (NMPA) to conduct a Phase I clinical study for the treatment of advanced\/metastatic solid tumors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=49798","og_locale":"en_US","og_type":"article","og_title":"Henlius HLX37 Bispecific NMPA Approval Targets Advanced Solid Tumors","og_description":"Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that its self-developed investigational new drug, HLX37 (Recombinant Humanized Anti-PD-L1 and Anti-VEGF Bispecific Antibody), has received approval from the China National Medical Products Administration (NMPA) to conduct a Phase I clinical study for the treatment of advanced\/metastatic solid tumors.","og_url":"https:\/\/flcube.com\/?p=49798","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-02T14:48:48+00:00","article_modified_time":"2025-12-02T14:48:49+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0210.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=49798#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=49798"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Henlius HLX37 Bispecific NMPA Approval Targets Advanced Solid Tumors","datePublished":"2025-12-02T14:48:48+00:00","dateModified":"2025-12-02T14:48:49+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=49798"},"wordCount":343,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=49798#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0210.webp","keywords":["Cancer","Clinical trial approval \/ initiation","Henlius Biotech","HKG: 2696","Multi-specific antibodies","PD-1\/L1"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=49798#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=49798","url":"https:\/\/flcube.com\/?p=49798","name":"Henlius HLX37 Bispecific NMPA Approval Targets Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=49798#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=49798#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0210.webp","datePublished":"2025-12-02T14:48:48+00:00","dateModified":"2025-12-02T14:48:49+00:00","description":"Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that its self-developed investigational new drug, HLX37 (Recombinant Humanized Anti-PD-L1 and Anti-VEGF Bispecific Antibody), has received approval from the China National Medical Products Administration (NMPA) to conduct a Phase I clinical study for the treatment of advanced\/metastatic solid tumors.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=49798#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=49798"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=49798#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0210.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0210.webp","width":1080,"height":608,"caption":"Henlius HLX37 Bispecific NMPA Approval Targets Advanced Solid Tumors"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=49798#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Henlius HLX37 Bispecific NMPA Approval Targets Advanced Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0210.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49798","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49798"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49798\/revisions"}],"predecessor-version":[{"id":49800,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49798\/revisions\/49800"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/49799"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49798"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49798"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49798"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}